secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2024-12-26T23:59:59+00:00
Accession:  0001104659-24-131705
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Therapeutics appoints interim VP of Finance, principal accounting officer
--------------------------------------------------------------------------------

- Natalie McAndrew appointed interim VP of Finance effective Jan 1, 2025.
- She will serve as principal financial officer and principal accounting officer.
- Ms. McAndrew is a Senior Director at Danforth Advisors, providing finance and accounting services under a master services agreement.
- Her background includes roles at Apertura Gene Therapy, Baudax Bio, Tmunity Therapeutics, Spark Therapeutics.
- The services agreement with Danforth can be terminated by either party with 30 days cause or 60 days without cause.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924131705/0001104659-24-131705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924131705/tm2432018d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-131705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer